trial
as of 2026-07-01A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia
NCTId NCT00088621
at a glance
Phase 2 · Completed
Enrollment 61 (actual)
Sponsored by Sumitomo Pharmaceuticals America
Primary completion 2005-10
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
61 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2004-07
Primary completion
2005-10
Eligibility
ALL · 18 Years · 64 Years
Interventions & indications
Drugs
Indications
Sponsors
Sumitomo Pharmaceuticals AmericaLead Sponsor
Investigators
1
Medical Director, MDStudy Director
Sites
20 total
Birmingham, United StatesLittle Rock, United StatesCerritos, United StatesGarden Grove, United StatesLa Mesa, United StatesSan Diego, United StatesSan Diego, United StatesUpland, United StatesWashington D.C., United StatesFort Lauderdale, United StatesNorth Miami, United StatesTampa, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
61
Phase
PHASE2
Primary Completion Date
2005-10
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
indication
indication
indication
investigator
person